<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061190</url>
  </required_header>
  <id_info>
    <org_study_id>BIAS1.0</org_study_id>
    <secondary_id>ZS EK 11 165/09</secondary_id>
    <secondary_id>2008-007031-41</secondary_id>
    <nct_id>NCT01061190</nct_id>
  </id_info>
  <brief_title>Beta Blockers In Acute Ischemic Stroke</brief_title>
  <acronym>BIAS</acronym>
  <official_title>Beta-Blocker in Acute Ischemic Stroke - a Prospective, Randomized, Double-blinded, Placebo-controlled Safety and Efficacy Trial of Early Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wilhelm Haverkamp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to assess the safety and efficacy of neuro- and
      cardioprotective effects of propranolol in acute ischemic stroke. Furthermore, exploratory
      analyses of cardiologic-electrophysiologic and immunologic parameters will be performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this trial is to assess the efficacy and safety of propranolol in
      middle cerebral artery stroke patients. The primary hypothesis is as follows: Early
      administration of propranolol reduces the frequency of cardiovascular and/or neurological
      complications including vascular death in the first 30 days after acute ischemic stroke.
      Secondary hypotheses are as follows: Early administration of propranolol improves
      neurological and functional outcome of patients with acute ischemic stroke. Early
      administration of propranolol reduces post-stroke immunodepression and therefore lowers the
      rate of pneumonia after acute ischemic stroke, without increasing the frequency of
      auto-aggressive, CNS antigen-specific T cells. Early administration of propranolol influences
      alterations in cardiologic, electrophysiologic phenomenons as a reaction to autonomic
      dysregulation after acute ischemic stroke. Early administration of Propranolol reduces growth
      of infarct as determined by MRI examinations in the first 6 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite incidence of cardiovascular and/or neurological complications including vascular death</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mRS and lethality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of SAEs and treatment withdrawals</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunological &amp; cardiological parameters</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>oral application of 160 mg Propranolol for 30 days</description>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptom onset within 18 hours

          -  Acute ischemic MCA-territory stroke

          -  Patients with suspected stroke in MCA-territory and a) NIHSS &gt; 3 or b) imaging
             evidence of MCA-infarction

        Exclusion Criteria:

          -  Patients already receiving beta-blockers

          -  Anti-arrhythmic, antiinfectious, antiinflammatory or immunosuppressive therapy

          -  Patients with a major heart disease, hypotension, bradycardia or any contraindication
             to the use of Propranolol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilhelm Haverkamp, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité, University Berlin, Center for Stroke Research Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité, University Berlin, Center for Stroke Research Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2010</study_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Wilhelm Haverkamp</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

